BNP Paribas raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,251 shares of the company's stock after purchasing an additional 1,608 shares during the period. Eli Lilly and Company accounts for...

Lam Research stock is trading near USD 290 after a recent pullback, while fresh analyst moves and a

Bank OZK acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,291 shares of the company's stock, valued at approximately $14,742,000. Eli Lilly and Company comprises about 4.4% of Bank OZK's investment portfolio, making the stock its 2nd...

Eli Lilly (NYSE:LLY) moves to diversify beyond metabolic disease with a new acquisition targeting autoimmune and allergic disease, even as shares dipped on deal spending.

Eli Lilly will acquire Merida Biosciences in a deal valued at up to $2.875 billion, including upfront and milestone payments. The acquisition will add Merida’s antibody-degradation platform and lead autoimmune program MER511 to Lilly’s immunology pipeline.

Eli Lilly has agreed to acquire Merida Biosciences, a developer of precision therapies for serious autoimmune and allergic diseases, for up to $2.875 billion.

Eli Lilly (NYSE:LLY) is in focus after a current corporate update, with sector conditions and broader market themes framing discussion around the company today today.

Eli Lilly and Company will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. Ilya Yuffa, Lilly's executive vice president and president of Lilly USA and Global Customer Capabilities, will join a fireside chat at 1:50 p.m. Eastern time. The event will be webcast live and available for replay on Lilly's investor website. This participation highlights Lilly's ongoing commitment to advancing healthcare innovations and communicating with investors about their progress in treating major health challenges like diabetes, obesity, Alzheimer's, immune disorders, and cancer.

Jim Cramer is flagging an Amgen drug that Wall Street has largely ignored, and he thinks the cardiovascular opportunity behind it could rival the most valuable pharmaceutical market ever created.

Eli Lilly (NYSE:LLY) stayed in focus as its oral obesity pill met late-stage trial goals, triggering global filings and spotlighting a metabolic franchise.